Emily is a Principal in Trinity’s strategic advisory practice, based in Trinity’s Waltham office. Emily has gained extensive experience in corporate strategy, evaluating and prioritizing opportunity via both franchise-level market evolution assessments as well as product-level asset diligence. She has partnered with clients to build and maintain robust infrastructures to support product launches, while developing a strong background in major therapeutic areas including immunology, neurology, hematology and oncology. Prior to joining Trinity, Emily received a PhD in Biomedical Engineering from Boston University, completing research in nanoparticle drug delivery of chemotherapy and developing a novel platform for drug delivery across the blood-brain barrier.